Information Journal Paper
APA:
Copy. (2017). RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents. NEUROPHARMACOLOGY, 118(-), 188-198. SID. https://sid.ir/paper/730942/en
Vancouver:
Copy. RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents. NEUROPHARMACOLOGY[Internet]. 2017;118(-):188-198. Available from: https://sid.ir/paper/730942/en
IEEE:
Copy, “RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents,” NEUROPHARMACOLOGY, vol. 118, no. -, pp. 188–198, 2017, [Online]. Available: https://sid.ir/paper/730942/en